TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
A veteran in cell therapy and oncology commercialisation
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Company working on COVID vaccine INO 4800
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
The goal for the project is the identification and optimization of anti-viral compounds.
Filing for WHO Emergency Use Authorisation this month
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
